Jan 23 2023
CellCentric's new oral cancer therapy inobrodib
Our host Richard Staines, Account Director at Optimum, discusses the latest clinical findings from inobrodib, an oral cancer therapy developed by the UK biotech CellCentric.In our first episode, we hear from Jan Ross, a patient who discusses the pressing need for new therapies for multiple myeloma with fewer side effects. We also talked to top cancer experts – Tim Somervaille of the Christie Hospital in Manchester, Karen Knudsen, Chief Executive of the American Cancer Society, Dr Leif Bergsagel, consultant in the Division of Hematology and Medical Oncology, at the Mayo Clinic in Arizona, and Will West, CEO of CellCentric.Despite recent medical advances, treating haematological cancer remains a considerable challenge. CAR-T cell therapies have shown incredible efficacy against some forms of blood cancer, but side-effects are fearsome, and they don’t always work. Conventional therapies may require injections and regular inconvenient visits to the hospital. And CAR-T cell therapies are hugely expensive for healthcare systems to buy and administer to patients because of the workload for staff monitoring side effects. A UK biotech, CellCentric has seen an opening for an oral therapy, based on a small molecule drug, that could treat multiple myeloma and could be taken by patients in their own home.https://www.optimumcomms.com/podcast / www.cellcentric.comFollow us and subscribe for new episodes highlighting the latest innovation and developments in life sciences, with industry leaders of the healthcare sector.Available on all major platforms: Apple, Spotify, Google, Amazon Music, Tune In, Castbox, Deezer and more! Follow and Subscribe today. #optimumperspectivespodcast Hosted on Acast. See acast.com/privacy for more information.